Cystatin C as a Marker of Hemodialysis Adequacy in Adults

Authors

1 Department of Nephrology and internal Medicine, Faculty of Medicine for boys, Al-Azhar University, Cairo, Egypt

2 Department of Clinical pathology, Faculty of Medicine for boys, Al-Azhar University, Cairo, Egypt.

Abstract

Background; Cystatin C (CyC) level in plasma is an emerging measure for evaluating kidney function. However, its usefulness in determining how well hemodialysis is working for individuals with end-stage renal disease has not yet been proven, Aim and objectives: Aim of the study was to evaluate cystatin C as a marker of adequacy of hemodialysis (HD) in adults. Subjects and methods: This study started between first of May 2022 and first of August 2022 and was conducted on 90 patients; 45 of them at Al-Hussain university hospital in Cairo and 45 of them at Arab Organization for Industrialization hospital in Cairo, all patients were selected from hemodialysis units in both hospitals. Results: There was a substantial decrease in both groups (p 0.001) when the mean values of serum urea, cystatin C, urea reduction ratio (URR), cystatin C reduction ratio (CCRR), and Kt/V were compared before and after the dialysis session. Our findings demonstrated that pre-dialytic mean blood levels of CyC and urea in our adult patients undergoing high-flux hemodialysis (HFH) were significantly lower than those undergoing low-flux hemodialysis (LFH). Conclusion: Our findings indicated improved renal parameters as well as higher MM clearance. In our study, the effectiveness of the CCRR is assessed as a measure of the sufficiency of HD sessions for individuals on HFH. We also discovered that because CyC was not considerably eliminated in LFH, it cannot be employed as a measure of toxin clearance

Files

Share

How to cite

Statistics